PsychoGenics is proud to be the preclinical CRO partner for the NIH/NINDS Preclinical Screening Platform for Pain (PSPP) program. The PSPP program facilitates the identification of potential non-opioid, non-addictive treatments (small molecules, biologics, natural products, or devices) for acute and chronic pain conditions and provides academia and industry a rigorous preclinical screening resource. If your compound is eligible for the program, preclinical studies approved by the program can be conducted by PsychoGenics, at no cost to you. To determine eligibility, please contact the program directly. PSPP involves collaborators worldwide, from academia, industry, government institutions, and even small businesses. The blinded and confidential preclinical evaluations of assets are performed by contract organizations under the direction of the National Institute of Neurological Disorders and Stroke (NINDS).
Unlocking the Future of Pain Disorder Research with PsychoGenics
Our involvement in and contributions to the PSPP initiative has enabled the expansion of our capabilities and expertise, allowing us to enhance support for your pain research program. Collaborate with PsychoGenics, and you’re joining forces with leaders in pain research.
Explore our areas of pain research expertise: